Trial Profile
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2023
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Capmatinib (Primary) ; Ieramilimab (Primary) ; Lacnotuzumab (Primary) ; Spartalizumab (Primary) ; Taminadenant (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 22 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 18 Nov 2022 Planned End Date changed from 14 Oct 2022 to 6 Feb 2023.
- 18 Nov 2022 Planned primary completion date changed from 14 Oct 2022 to 6 Feb 2023.